Cosmos Health签订收购2型糖尿病疗法DIABIT-IS X的最终协议-动脉网

Cosmos Health Enters into Definitive Agreement to Acquire Type-2 Diabetes Treatment DIABIT-IS X

BioSpace 等信源发布 2023-12-20 09:50



可切换为仅中文







CHICAGO, IL / ACCESSWIRE / December 20, 2023 / Cosmos Health Inc. ('Cosmos Health' or the 'Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into a definitive agreement, subject to customary closing conditions, with a related party to acquire the license and rights for 'DIABIT-IS X', a drug used in the treatment of type-2 diabetes..

伊利诺伊州芝加哥/ACCESSWIRE/2023年12月20日/Cosmos Health Inc.（“Cosmos Health”或“公司”）（纳斯达克：COSM），一家多元化、垂直整合的全球医疗保健集团，从事创新研发，拥有专有制药和营养保健品牌，医疗保健产品的制造商和分销商，以及远程保健平台的运营商，今天宣布，根据惯例的交割条件，该公司已与关联方达成最终协议，以获得用于治疗2型糖尿病的药物“DIABIT-IS X”的许可证和权利。。

DIABIT-IS X is one the first generics to be launched in Europe following the European patent expiration in June 2024 of the branded 'Januvia' owned by Merck. Januvia, along with its sister drug Janumet, generated combined global sales of $4.5 billion in 2022, and is approaching the expiration of its primary patent, held by Merck.

自2024年6月默克（Merck）旗下品牌“Januvia”的欧洲专利到期后，DIABIT-IS X是欧洲首批推出的仿制药之一。2022年，Januvia及其姊妹药Janumet的全球总销售额达到45亿美元，其主要专利（由默克公司持有）即将到期。

In this context, Cosmos Health, as one of the first movers through the acquisition of DIABIT-IS X, is well-positioned to capture a significant share of the European market..

在这种情况下，宇宙健康作为收购DIABIT-IS X的第一批推动者之一，处于占领欧洲市场重要份额的有利地位。。

DIABIT-IS X is a medicine that contains the active substance sitagliptin. It will be available in tablets to be used in patients with type-2 diabetes to improve the control of blood glucose (sugar) levels. Type-2 diabetes occurs when the pancreas doesn't produce enough insulin or the body doesn't use insulin properly.

DIABIT-IS X是一种含有活性物质西他列汀的药物。它将制成片剂，用于2型糖尿病患者，以改善血糖（血糖）水平的控制。当胰腺不能产生足够的胰岛素或身体不能正确使用胰岛素时，就会发生2型糖尿病。

DIABIT-IS X, containing sitagliptin, inhibits the breakdown of incretin hormones which stimulate insulin production after meals. Sitagliptin boosts insulin when blood glucose is high and doesn't activate at normal blood sugar levels. It also helps reduce liver glucose production, assisting in blood glucose regulation for type-2 diabetes management..

含有西他列汀的DIABIT-IS X抑制肠促胰岛素激素的分解，肠促胰岛素激素刺激餐后胰岛素的产生。西他列汀在血糖高且在正常血糖水平下不激活时可增强胰岛素。它还有助于减少肝脏葡萄糖的产生，有助于2型糖尿病管理的血糖调节。。

Greg Siokas, Chief Executive Officer of Cosmos Health, stated: 'We are expanding into new markets to enhance and diversify our revenue streams. We are pleased to announce a definitive agreement to acquire DIABIT-IS X, which positions Cosmos as one of the first companies to launch a generic Type-2 diabetes medicine in Europe.

Cosmos Health首席执行官格雷格·希奥卡斯（GregSiokas）表示：“我们正在拓展新市场，以增强我们的收入来源并使其多样化。我们很高兴宣布收购DIABIT-IS X的最终协议，该协议将Cosmos定位为首批在欧洲推出仿制药2型糖尿病药物的公司之一。

Considering the multi-billion-dollar market size, we anticipate generating substantial profits from this investment.'.

考虑到数十亿美元的市场规模，我们预计这项投资将产生可观的利润。”。

About Cosmos Health Inc.

关于Cosmos Health Inc。

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Chicago, Illinois, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe® and C-Sept®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency, it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union.

Cosmos Health Inc.（纳斯达克股票代码：COSM）于2009年在伊利诺伊州芝加哥成立，是一家多元化、垂直整合的全球医疗保健集团。该公司拥有一系列专有制药和营养保健品牌，包括Sky Premium Life®、Mediterranation®、bio bebe®和C-Sept®。通过其子公司Cana Laboratories S.A.，获得欧洲良好生产规范（GMP）许可并获得欧洲药品管理局（European Medicines Agency）认证，它在欧盟范围内生产药品、食品补充剂、化妆品、杀菌剂和医疗器械。

Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products.

Cosmos Health还通过其在希腊和英国的子公司向零售药店和批发分销商分销广泛的药品和副药品，包括品牌仿制药和非处方药。此外，该公司还建立了针对肥胖、糖尿病和癌症等主要健康疾病的研发伙伴关系，并专注于新型专利营养保健品，专业根提取物，专有复合仿制药和创新OTC产品的研发。

Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK.

Cosmos Health还通过收购总部位于美国德克萨斯州的ZipDoctor，Inc.进入了远程保健领域。凭借全球分销平台，该公司目前正在欧洲、亚洲和北美扩张，并在塞萨洛尼基、希腊雅典和英国哈洛设有办事处和分销中心。

More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, and www.zipdoctor.co, as well as LinkedIn and X..

Forward-Looking Statements

前瞻性声明

With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words 'believes,' 'expects,' 'anticipates,' 'intends,' 'projects,' 'estimates,' 'plans' and similar expressions or future or conditional verbs such as 'will,' 'should,' 'would,' 'may' and 'could', are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing.

除本新闻稿中包含的历史信息外，本文所述事项可能包含经修订的《1933年证券法》第27A节和经修订的《1934年证券交易法》第21E节所指的前瞻性陈述。前面、后面或以其他方式包括“相信”、“期望”、“预期”、“打算”、“项目”、“估计”、“计划”和类似表达或未来或条件动词（如“意志”、“应该”、“将会”、“可能”和“可能”）的陈述通常具有前瞻性，而不是历史事实，尽管并非所有前瞻性陈述都包括上述内容。

These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies.

这些声明涉及未知的风险和不确定性，这些风险和不确定性可能会因公司无法控制的各种原因而单独或实质性地影响本文讨论的事项，包括但不限于公司筹集足够资金以实施其业务计划的能力，新型冠状病毒大流行的影响和乌克兰战争，公司的业务、运营和总体经济，以及公司成功开发和商业化其专有产品和技术的能力。

Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov).

提醒读者不要过度依赖这些前瞻性陈述，因为实际结果可能与本文所述的前瞻性陈述中描述的结果存在重大差异。敦促读者阅读该公司向SEC提交的文件中规定的风险因素，这些文件可在SEC网站（www.SEC.gov）上找到。

The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise..

无论是由于新信息、未来事件还是其他原因，公司均不打算或有义务更新或修订任何前瞻性声明。。

Investor Relations

投资者关系

Paul Lampoutis

保罗·兰普蒂斯

Capital Link, Inc.

Capital Link公司。

230 Park Avenue, Suite 1540

公园大道230号1540室

New York, N.Y. 10169

纽约州10169

Tel.: (212) 661-7566